Clinical Trial Update: MInimal Residual Disease Adapted Strategy [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial update for a Minimal Residual Disease adapted strategy in Multiple Myeloma, sponsored by Intergroupe Francophone du Myelome. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: Intergroupe Francophone du Myelome | Conditions: Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING